Date Title Description PDF
08 Nov 2023 On P&L The Company releases the first nine months 2023 financial results presentation Download
26 Jul 2023 On P&L The Company releases the press release related to the first half 2023 financial results Download
26 Jul 2023 On P&L The Company releases the first half 2023 financial results presentation Download
26 Jul 2023 On buy-back programmes The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program.   Download
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download

Pages

Date Title Description PDF
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download
07 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 31 January 2022 and 4 February 2022 Download
31 Jan 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 24 January 2022 and 28 January 2022 Download

Pages

Date Title Description PDF
21 Dec 2011 Acuerdos estratégicos con terceros (2) Download
21 Dec 2011 Acuerdos estratégicos con terceros Download
08 Nov 2011 Información sobre resultados (2) Download
08 Nov 2011 Información sobre resultados Download
08 Nov 2011 Composición de otros órganos de gestión y control Download

Pages